CLINICAL_TRIALS
trial_result
· 2025-12-09
Clinical Trial Update: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy [Phase 3]
Summary
A Phase 3 trial evaluating the safety and efficacy of OMS721 (narsoplimab) in IgA nephropathy has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Omeros Corporation | Conditions: IgA Nephropathy | Phase 3 | Status: TERMINATED | Results posted: 2025-12-09